Vanderbilt Vaccine Research Program

A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age. Read More

Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by C. Buddy Creech, MD, MPH, has found. Read More

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Read More

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine. Read More

Vanderbilt University Medical Center is recruiting volunteers to participate in a national study of an investigational vaccine against the H7N9 influenza virus, also known as “bird flu.” Read More

Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world. Read More

New multicenter research that includes Vanderbilt University Medical Center (VUMC) investigators, could change treatment approaches to simple skin abscesses, infections often caused by Staphylococcus aureus (staph) bacteria. Read More

Researchers at Vanderbilt University Medical Center (VUMC) are leading a multicenter clinical trial to evaluate whether a shorter course of antibiotics — five days instead of 10 — is effective at treating community-acquired pneumonia (CAP) in children who show improvement after the first few days of taking antibiotics. Read More

Vanderbilt researchers could be one step closer to finding a way to fight the deadly Ebola virus – thanks to two Ebola victims from Nigeria, who faced death and survived. Vanderbilt researchers developed a unique method of isolating potent Ebola-fighting antibodies from survivors’ blood and they believe these newest… Read More

Buddy Creech, M.D., MPH, associate professor of Pediatrics, has been named director of the Vanderbilt Vaccine Research Program (VVRP) in the Division of Pediatric Infectious Diseases. Read More

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus. Read More

The Vanderbilt Vaccine Research Program has received a major contract from the National Institutes of Health to continue its work as one of the nation’s Vaccine and Treatment Evaluation Units. Read More

Vanderbilt University Medical Center has been selected by the Centers for Disease Control and Prevention (CDC), to lead a consortium of top national experts in vaccine safety in performing timely reviews of adverse vaccine events. Read More

Vanderbilt is taking part in a national study to test in older adults the use of a vaccine designed to protect children against a common cause of pneumonia. Read More

Vanderbilt researchers are seeking healthy adults ages 18-49 for a study testing a new vaccine against H5N1 influenza, a strain which has the potential to be the next pandemic flu virus. Read More